Research led by National Cheng Kung University, Taiwan, suggests glucagon-like peptide 1 (GLP-1) receptor agonists can protect against spine fracture risk.

“Type 2 diabetes is a well-established risk factor for vertebral fractures associated with long-term disability and increased mortality,” explain Yu Chang, MD, a researcher and clinician at National Cheng Kung University, and colleagues in JAMA Surgery .

“While GLP-1 receptor agonists have demonstrated therapeutic benefits beyond glycemic control, their role in bone health remains uncertain, and evidence regarding their association with vertebral fracture risk has been inconsistent.”

Chang and colleagues carried out a study using electronic health record data to assess whether GLP-1 agonist use impacted spine fracture risk in ind

See Full Page